as of 12-15-2025 10:27am EST
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
| Founded: | 1924 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 719.7M | IPO Year: | N/A |
| Target Price: | $18.50 | AVG Volume (30 days): | 781.4K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.62 | EPS Growth: | 20.90 |
| 52 Week Low/High: | $9.20 - $21.23 | Next Earning Date: | 11-25-2025 |
| Revenue: | $1,080,400,000 | Revenue Growth: | -3.80% |
| Revenue Growth (this year): | 2.18% | Revenue Growth (next year): | 0.09% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how EMBC stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EMBC Embecta Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.